|
#1
31.03.2008, 17:41
|
||||
|
||||
|
Graves’ Orbitopathy
Consensus Statement of the European Group
on Graves’ Orbitopathy (EUGOGO) on Management of Graves’ Orbitopathy* [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] 
|
|
#2
31.03.2008, 17:57
|
||||
|
||||
|
Ñïàñèáî, ßíà Ñåðåãååâíà !! ( äîâîëüíî ìóðëûêàÿ - à ó íàñ íà Òèðîíåòå ñîêðàùåííîå èçëîæåíèå íà ðóññêîì îïóáëèêîâàíî )
|
|
#3
31.03.2008, 18:10
|
||||
|
||||
|
Ìîëîäöû!
 Òîãäà äðóãîå: Differentiated Thyroid Cancers 11–20mm in Diameter Have Clinical and Histopathologic Characteristics Suggesting Higher Aggressiveness than Those <10mm Objective: To compare characteristics and outcomes of differentiated thyroid cancers <10mm with those 11– 20mm in diameter. Design: Retrospective chart review of 426 patients with thyroid carcinoma <20mm diagnosed and treated between 1990 and 2004 in one university clinic. Main outcomes: Lymph node metastases were more frequent at diagnosis in 11–20mm than in <10mm cancers ( p < 0.001). The prevalence of distant metastases did not differ between <10mm and 11–20mm cancers. One hundred and thirty-three patients (73%) with tumors 11–20mm were disease free 2 years after 131I treatment, and no recurrence has been observed over 2–14 years of follow-up. Forty-one patients (22%) with cancers 11–20mm (N1 or M1) required 2–4 years to become disease free. Neck lymph node recurrence was observed in nine patients (4.9%) 4months to 14 years after surgery and 131I therapy. Four patients (1.6%) with cancers <10mm in diameter had cancer recurrence ( p¼0.05 compared to the 11–20mm cancers). Based on the presence of distant metastases at diagnosis and recurrence of disease during follow-up, cancers 11–20mm in diameter seemed more aggressive than those <10mm ( p < 0.05). Conclusion: Cancers 11–20mm seem more aggressive than those <10mm. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
#4
31.03.2008, 18:20
|
||||
|
||||
|
 ñóùíîñòè, ýòî åùå êîïåéêà â cut off äëÿ ïóíêöèè è â îëèìïèéñêîå ñïîêîéñòâèå ïðè ìèêðîêàðöèíîìàõ
|
|
#6
31.03.2008, 19:03
|
||||
|
||||
|
Ó íàñ êàìåðà ïîëåòåëà. Ìàëî ÷òî ïðîèñõîäèò. ×èòàþ æóðíàëü÷èêè.
Âîò êàêóþ øòóêó èíòåðåñíóþ íàøëà: 6-ëåòíèé ìàëü÷èê ñ 8ìì óçëîì â ïðàâîé äîëå øèòîâèäíîé æåëåçû íà ñîíîãðàììå. [Èçîáðàæåíèÿ äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì] Íà ñöèíòèãðàôèè - ãèïîôóíöèÿ óçëà. [Èçîáðàæåíèÿ äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì] [Èçîáðàæåíèÿ äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì] Ectopic intrathyroidal thymus tissue that forms mass lesions as a consequence of aberrant thymic migration during embryogenesis.
|
|
#7
31.03.2008, 19:16
|
||||
|
||||
|
ßíà!!! ß óæå çàðûëàñü â àòëàñû è ïîêðàñíåëà îò ñòûäà, ÷òî íå ìîãó îïîçíàòü!! ( ÿ âîîáùå ïëîõî ïîìíþ êàðòèíêè ãèñòîëîãè÷åñêèå )
|
Ëèíåéíûé âèä
